PE64396A1 - Proteina accesoria del receptor de la interleucina 1 - Google Patents

Proteina accesoria del receptor de la interleucina 1

Info

Publication number
PE64396A1
PE64396A1 PE1996000031A PE00003196A PE64396A1 PE 64396 A1 PE64396 A1 PE 64396A1 PE 1996000031 A PE1996000031 A PE 1996000031A PE 00003196 A PE00003196 A PE 00003196A PE 64396 A1 PE64396 A1 PE 64396A1
Authority
PE
Peru
Prior art keywords
accessory protein
receptor
polynucleotide
same
mentioned
Prior art date
Application number
PE1996000031A
Other languages
English (en)
Spanish (es)
Inventor
Richard Anthony Chizzonite
Grace Wong Ju
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE64396A1 publication Critical patent/PE64396A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PE1996000031A 1995-01-23 1996-01-15 Proteina accesoria del receptor de la interleucina 1 PE64396A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37626895A 1995-01-23 1995-01-23

Publications (1)

Publication Number Publication Date
PE64396A1 true PE64396A1 (es) 1997-01-28

Family

ID=23484321

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000031A PE64396A1 (es) 1995-01-23 1996-01-15 Proteina accesoria del receptor de la interleucina 1

Country Status (19)

Country Link
EP (1) EP0808365A1 (fr)
JP (1) JPH10512453A (fr)
AR (1) AR003919A1 (fr)
AU (1) AU4537096A (fr)
BR (1) BR9606837A (fr)
CA (1) CA2210724A1 (fr)
CO (1) CO4480033A1 (fr)
CZ (1) CZ208197A3 (fr)
EA (1) EA199700265A1 (fr)
FI (1) FI973089A0 (fr)
HU (1) HUP9702458A2 (fr)
IL (1) IL116796A0 (fr)
MX (1) MX9705501A (fr)
NO (1) NO973404L (fr)
PE (1) PE64396A1 (fr)
PL (1) PL321538A1 (fr)
TR (1) TR199700652T1 (fr)
WO (1) WO1996023067A1 (fr)
ZA (1) ZA96333B (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974682B1 (en) 1996-08-26 2005-12-13 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
AU7011696A (en) * 1996-08-26 1998-03-19 Human Genome Sciences, Inc. Soluble interleukin-1 receptor accessory molecule
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
EP0979282A1 (fr) 1997-04-30 2000-02-16 F. Hoffmann-La Roche Ag Chemokine st38.2 du rat
US6280955B1 (en) * 1997-12-16 2001-08-28 Tularik Inc. Interleukin-1 receptor accessory proteins, nucleic acids and methods
EP1042477A1 (fr) 1997-12-23 2000-10-11 Immunex Corporation Adn et polypeptides sigirr
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2002253842A1 (en) 2000-10-31 2002-08-28 Immunex Corporation Il-1 receptor accessory protein
GB2375604A (en) * 2001-05-18 2002-11-20 Warner Lambert Co Methods for screening using interleukin soluble trimolecular complex
JP4212470B2 (ja) 2001-06-26 2009-01-21 アムジェン フレモント インク． Ｏｐｇｌへの抗体
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2003014309A2 (fr) * 2001-08-07 2003-02-20 Immunex Corporation Recepteurs de l'interleukine-1 dans le traitement de maladies
ATE549033T1 (de) 2002-09-06 2012-03-15 Amgen Inc Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
TR201816556T4 (tr) 2004-04-02 2018-11-21 Swedish Orphan Biovitrum Ab Publ Il-1ra agregasyonunun azaltilmasina yöneli̇k yöntemler
US8618054B2 (en) 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
CA2607113C (fr) * 2004-05-05 2013-11-12 Valorisation-Recherche, Societe En Commandite Antagonistes du recepteur de l'interleukine-1, compositions, et methodes de traitement
EP2366786A3 (fr) * 2005-05-05 2012-08-29 VALORISATION HSJ, Société en Commandite Modulateurs de récepteur de cytokine et utilisations associées
PE20070684A1 (es) 2005-11-14 2007-08-06 Amgen Inc MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
EP2271673B1 (fr) 2008-03-26 2016-02-24 Cellerant Therapeutics, Inc. Récepteurs de cytokine associés aux troubles prolifératifs hématologiques myélogènes et utilisations correspondantes
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
GB2472856B (en) * 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
CA2824719C (fr) * 2011-01-19 2020-06-02 Cantargia Ab Anticorps anti-il1rap et leur utilisation dans le traitement de tumeurs solides
MX2013013627A (es) * 2011-06-21 2014-04-25 Oncofactor Corp Composiciones y metodos para la terapia y diagnostico de cancer.
WO2013006490A2 (fr) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Anticorps se liant spécifiquement à tim3
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
EP3294906A1 (fr) 2015-05-11 2018-03-21 Natera, Inc. Procédés et compositions pour la détermination de la ploïdie
EP3313887A2 (fr) 2015-06-26 2018-05-02 MAB Discovery GmbH Anticorps monoclonaux anti-il-1racp
EP3241845A1 (fr) 2016-05-06 2017-11-08 MAB Discovery GmbH Anticorps anti-il-1r3 humanisés
WO2018022982A1 (fr) 2016-07-29 2018-02-01 Trustees Of Boston University L'hématopoïèse clonale associée à l'âge accélère le développement d'une maladie cardio-métabolique
EP3401332A1 (fr) 2017-05-08 2018-11-14 MAB Discovery GmbH Anticorps anti-il-1r3 destinés à être utilisés dans des conditions inflammatoires
JP2020524519A (ja) 2017-06-20 2020-08-20 ザ メディカル カレッジ オブ ウィスコンシン，インコーポレイテッドＴｈｅ Ｍｅｄｉｃａｌ Ｃｏｌｌｅｇｅ ｏｆ Ｗｉｓｃｏｎｓｉｎ， Ｉｎｃ． 全セルフリーｄｎａによる移植合併症リスクの評価
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2021236962A1 (fr) 2020-05-20 2021-11-25 The Medical College Of Wisconsin, Inc. Compositions et méthodes d'inhibition du syndrôme de libération des cytokines
WO2022247937A1 (fr) * 2021-05-28 2022-12-01 Biocytogen Jiangsu Co., Ltd. Animal non humain génétiquement modifié exprimant l'il1rap humaine ou chimérique

Also Published As

Publication number Publication date
NO973404D0 (no) 1997-07-23
AR003919A1 (es) 1998-09-30
CO4480033A1 (es) 1997-07-09
WO1996023067A1 (fr) 1996-08-01
ZA96333B (en) 1996-07-23
FI973089A (fi) 1997-07-22
EA199700265A1 (ru) 1998-04-30
MX9705501A (es) 1997-10-31
HUP9702458A2 (hu) 1998-04-28
JPH10512453A (ja) 1998-12-02
PL321538A1 (en) 1997-12-08
IL116796A0 (en) 1996-05-14
CA2210724A1 (fr) 1996-08-01
AU4537096A (en) 1996-08-14
BR9606837A (pt) 1998-05-26
EP0808365A1 (fr) 1997-11-26
FI973089A0 (fi) 1997-07-22
NO973404L (no) 1997-07-23
TR199700652T1 (xx) 1998-02-21
CZ208197A3 (en) 1997-11-12

Similar Documents

Publication Publication Date Title
PE64396A1 (es) Proteina accesoria del receptor de la interleucina 1
AR248044A1 (es) Una secuencia de adn que codifica anticuerpos monoclonales humanizados contra interleuquinas humanas, metodo de obtencion y de seleccion de dichos anticuerpos, vector recombinante y celula huesped.
ES2054878T3 (es) Expresion de la proapolipoproteina a-i humana.
AR096027A2 (es) Proteínas insecticidas quiméricas de bacillus thuringiensis
DE68926303T2 (de) Peptide und antikörper, die die integrin-ligandbindung inhibieren
CA2096159A1 (fr) Peptides induisant des anticorps qui neutralisent les isolats de vih-1 divergents sur le plan genetique
IL86278A (en) Endowing cells with antibody specificity using chimeric t cell receptor
ES2054601T3 (es) Proteina con actividad de tipo citoquina, adn recombinante codante para esta proteina, celulas y microorganismos transformados.
IL98024A0 (en) Cd44-surface proteins,dna-sequences coding therefor,polypeptides coded by said dna sequences and diagnostic compositions containing the same
Porter The structure of the heavy chain of immunoglobulin and its relevance to the nature of the antibody-combining site. The Second CIBA Medal Lecture.
FI941048A (fi) Geloniinipolypeptidin koodaavia DNA-sekvenssejä
BR9500271B1 (pt) seqüência de dna recombinante, vetor, células procarióticas e de fungo transformadas e proteìna com atividade sacarose-isomerase e com atividade de platinase e/ou trehalulase.
EA201001190A1 (ru) Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков
James et al. Use of reversed-phase and ion-exchange batch extraction in the purification of bovine pituitary peptides
ATE478089T1 (de) Isolierte polypeptide auf der grundlage des neutralisierenden epitops des p17-proteins vom hiv geeignet als impfstoffe und neutralisierende anti-p17-antikörper, die besagtes epitop spezifisch erkennen
EP0815240A4 (fr) Nouvelles proteines humaines semblables a la kinase et dependantes de la cycline et leurs methodes d'application
NO975565L (no) Benstimulerende faktor
IL75553A (en) Dna sequence coding for a cholinesterase-like peptide, peptides produced by cells containing said dna and antibodies thereto
Sherman et al. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia
DE60031414D1 (de) Einkettige polypeptide enthaltend n-terminale troponin i fragmente und troponin c
AR025482A1 (es) Secuencia de adn que codifica una proteina capaz de ligarse a traf; vector que comprende dicha secuencia; celulas huespedes transformadas con dicho vector;proteinas iren codificadas por dicha secuencia; metodo para producir dicha proteina; anticuerpos especificos para dichas proteinas; metodo para m
DE69132874D1 (de) Für ein protein mit endochitinase-aktivität kodierendes rekombinantes gen
NZ508812A (en) Peptides for the prevention or treatment of HIV
US6319890B1 (en) Inhibition of binding of complement Factor H
Leone et al. Characterisation of an epitope recognised by a monoclonal antibody against horse alcohol dehydrogenase using peptides synthesised on solid support

Legal Events

Date Code Title Description
FD Application declared void or lapsed